ArticleJournal of Cancer2020
Independent prognostic implications of
Article in Journal of Cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed.
- Ribonucleotide Reductase Inhibition Triggers Ferroptosis in Genetically Defined Subsets of Non-Small Cell Lung Cancer.Cancer research communications · 2026Article
- Subtype-specific clinical significance of RRM1 and RRM2 expression in non-small cell lung cancer: a TCGA-based analysis.Genes & genomics · 2026Article
- Identification of RRM2 as a key regulator of malignant epithelial cells in gastric cancer through single‑cell transcriptomics.Oncology reports · 2026Article
- Multifaceted bioinformatic analysis uncover links m5C-related ferroptosis gene SLC2A1 to prognosis and immune infiltration in lung adenocarcinoma.Discover oncology · 2026Article
- A prognostic lncRNA signature associated with ribonucleotide reductase predicts overall survival and immune landscape in hepatocellular carcinoma.Frontiers in cell and developmental biology · 2026Article
- Integrated single-cell and multi-cohort analyses reveal CTCF as a key regulator of chemo-immunotherapy resistance in lung adenocarcinoma.Frontiers in cell and developmental biology · 2026Article
- CDC6 promotes the development and progression of clear cell renal cell carcinoma via upregulating RRM2.Human cell · 2025Article
- Chelerythrine Inhibits TGF-β-Induced Epithelial-Mesenchymal Transition in A549 Cells via RRM2.Pharmaceuticals (Basel, Switzerland) · 2025Article
- The role of B cell immunity in lung adenocarcinoma.Genes and immunity · 2025Review
- Multifaceted function of B cells in tumorigenesis.Frontiers of medicine · 2025Review
- Significance of Ribonucleoside-diphosphate Reductase Subunit M2 in Lung Adenocarcinoma.Current gene therapy · 2025Article
- DNA damage repair-related methylated genes RRM2 and GAPDH are prognostic biomarkers associated with immunotherapy for lung adenocarcinoma.Genetics and molecular biology · 2025Article
- The prognostic and clinical value of genes associate with immunity and amino acid Metabolism in Lung Adenocarcinoma.Heliyon · 2024Article
- Circular RNAs and cervical cancer: friends or foes? A landscape on circRNA-mediated regulation of key signaling pathways involved in the onset and progression of HPV-related cervical neoplasms.Cell communication and signaling : CCS · 2024Review
- Combination of gene/protein and metabolite multiomics to reveal biomarkers of nickel ion cytotoxicity and the underlying mechanism.Regenerative biomaterials · 2024Article
- A comprehensive analysis of ribonucleotide reductase subunit M2 for carcinogenesis in pan-cancer.PloS one · 2024Article
- Deciphering the Anticancer Arsenal ofInternational journal of medical sciences · 2024Article
- NPM3 as an Unfavorable Prognostic Biomarker Involved in Oncogenic Pathways of Lung AdenocarcinomaCombinatorial chemistry & high throughput screening · 2024Article
- Circ_0006646 Accelerates the Growth and Metastasis of Cervical Cancer by Elevating RRM2 Through miR-758-3p.Biochemical genetics · 2023Article
- Prognosis and personalized treatment prediction in lung adenocarcinoma: AnFrontiers in pharmacology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.